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ARTICLE
Pan-cancer analysis reveals cooperativity of both
strands of microRNA that regulate tumorigenesis
and patient survival
Ramkrishna Mitra 1, Clare M. Adams 1, Wei Jiang2, Evan Greenawalt1 & Christine M. Eischen 1✉
Recently, both 5p and 3p miRNA strands are being recognized as functional instead of only
one, leaving many miRNA strands uninvestigated. To determine whether both miRNA
strands, which have different mRNA-targeting sequences, cooperate to regulate pathways/
functions across cancer types, we evaluate genomic, epigenetic, and molecular profiles of
>5200 patient samples from 14 different cancers, and RNA interference and CRISPR screens
in 290 cancer cell lines. We identify concordantly dysregulated miRNA 5p/3p pairs that
coordinately modulate oncogenic pathways and/or cell survival/growth across cancers.
Down-regulation of both strands of miR-30a and miR-145 recurrently increased cell cycle
pathway genes and significantly reduced patient survival in multiple cancers. Forced
expression of all four strands show cooperativity, reducing cell cycle pathways and inhibiting
lung cancer cell proliferation and migration. Therefore, we identify miRNA whose 5p/3p
strands function together to regulate core tumorigenic processes/pathways and reveal a
previously unknown pan-cancer miRNA signature with patient prognostic power.
https://doi.org/10.1038/s41467-020-14713-2 OPEN
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M icroRNA (miRNA) are small non-coding RNA thatregulate gene expression by binding target messengerRNA (mRNA) and typically inhibiting translation1,2.
Although individual miRNA are reported to have many critical
roles in tumorigenesis1,2, much remains unknown. Moreover,
there are >8300 miRNA identified in humans3, and each pre-
cursor miRNA consists of two mature miRNA strands (5p and
3p) that contain different mRNA-targeting sequences4,5. Recent
evidence has shown the historical belief that one strand is
degraded during miRNA biogenesis may not be correct4,5.
Instead, depending on the tissue/cell type, developmental stage, or
disease state both miRNA strands can be present or have altered
expression4,6,7. In cancer in particular, genomic instability, epi-
genetic modifications, and alterations in transcription factors
impact miRNA loci1,8,9, which can change the expression of
precursor miRNA, resulting in altered levels of both the 5p and
3p strands7. However, due to the study of typically only one
miRNA strand, the function of half of all miRNA has not been
explored, missing the likely significant contributions many have
to human cancers.
A limited number of studies have investigated the functions of
both miRNA strands of specific miRNA in specific cancers10–20.
For example, miR-31-5p and miR-31-3p are both upregulated in
oral squamous cell carcinoma, but one counteracts the oncogenic
function of the other17. The 5p and 3p strands of miR-582 and
miR-28 are downregulated in bladder and colorectal cancer,
respectively15,16. However, forced expression of miR-582-5p and
miR-582-3p inhibited bladder cancer cell proliferation and tumor
growth15, whereas forced expression of miR-28-5p, but not miR-
28-3p, reduced colorectal cancer cell proliferation16. In miR-17
transgenic mice, both the 5p and 3p strands are overexpressed
and the mice are predisposed to hepatocellular carcinoma18.
Moreover, forced co-overexpression of miR-17-5p and 3p strands
increased prostate cancer xenograft growth and invasion19.
Therefore, miRNA have complex mechanisms of actions and the
interplay between the 5p and 3p strands of individual miRNA in
cancers remains largely unexplored.
As many cancer types rely on fundamental oncogenic path-
ways, a core set of mature miRNA may exist that are consistently
dysregulated across cancer types and drive pan-cancer tumor-
igenesis by recurrently targeting and dysregulating genes in these
critical pathways21. Currently, it remains unclear whether both
strands of endogenous miRNA function cooperatively to regulate
core oncogenic processes and pathways during tumorigenesis
across cancers. To investigate this, we leveraged genome-scale
RNA interference (RNAi) and CRISPR-based loss-of-function
screens from hundreds of cell lines, and thousands of multi-omics
profiles from 14 different cancer types available in The Cancer
Genome Atlas (TCGA), and verified results with independent
data sets and biological experiments. We systematically identified
miRNA 5p/3p pairs that coordinately dysregulate oncogenic
pathways across cancer types and determined that both miRNA
strands of two top predicted miRNA cooperate to control cancer
cell proliferation and migration, and constitute a core miRNA
signature that correlates to patient survival across cancer types.
Results
miRNA 5p/3p pairs cooperatively modulate cancer cell growth.
With the analysis of 396 human and 47 mouse miRNA expres-
sion profiles across different cell types, generated by Functional
Annotation of the Mammalian Genome project22, we observed
global concordance in 5p/3p expression changes. The observed
concordance was significantly (P < 10−74, Wilcoxon rank-sum
test) higher compared with the background miRNA pairs,
which were selected randomly from different precursor miRNA
(Fig. 1a). We obtained consistent results by analyzing 5238 TCGA
miRNA expression profiles across 14 different cancer types
(Fig. 1b; Supplementary Fig. 1 and Supplementary Table 1). For
each cancer type, we analyzed 45−847 tumor and normal sam-
ples that had both miRNA and mRNA expression profiles. We
identified 78-196 (average= 135) significantly dysregulated (1.5-
fold-change with Benjamini–Hochberg (BH)23 adjusted P < 0.05)
mature miRNA from each cancer type (Supplementary Fig. 2).
Among those identified, 9–42 miRNA pairs (average= 23) ori-
ginated from the same precursor miRNA. Irrespective of whether
the 5p/3p pairs had significant dysregulation in cancer, their
expression fold-changes had high concordance (Spearman’s ρ=
0.74; correlation P= 5.89 × 10−289) (Fig. 1c and Supplementary
Fig. 3).
We investigated whether these concordantly dysregulated
miRNA 5p/3p pairs work together to regulate specific biological
functions. Genome-scale si/shRNA or CRISPR-based loss-of-
function screens for 290 diverse cancer cell lines were available
for the 9 cancer types we studied here (Methods section,
Supplementary Table 2)24–26. This massive-scale resource
provided an unprecedented opportunity to understand the
relationship between miRNA expression and cell viability/growth
from miRNA regulating genes that reduce the viability/growth of
specific cancer cells upon their inactivation. A gene with a lower
score in the screening data indicates the given cell line is more
dependent on that gene for its survival/growth. We predicted
cancer-specific miRNA-target gene sets and determined, using
the gene set enrichment analysis (GSEA)27 embedded into R
package WebGestaltR28, which target gene sets were significantly
(FDR < 0.1) overrepresented at the bottom of the ranked gene list
in the cancer cell lines of that cancer type (Methods section;
Fig. 1d). The results indicate the regulating miRNA of those gene
sets may negatively impact the growth and/or survival of the
corresponding cancer cell lines.
We identified 71 miRNA from RNAi and 80 miRNA from
CRISPR screening data with 66 being the same miRNA from both
screens whose expression potentially inhibits growth and/or
survival of cancer cell lines. We examined dysregulation patterns
of these miRNA in the tumor tissues in TCGA of the same cancer
types as the cell lines. We determined that 98% and 100% of the
miRNA derived from the RNAi and CRISPR screens, respectively,
had significant downregulation in the specific tumor type
compared with the corresponding normal tissue (Fig. 1e). We
also determined expression changes of the core enrichment genes
in the selected gene sets with significant normalized enrichment
scores (NES (FDR < 0.1)). From TCGA data, we observed that
99% and 100% of the genes identified from RNAi and CRISPR
screens, respectively, had significant upregulation in the corre-
sponding tumor types of the cell lines (Fig. 1e). Collectively, these
results suggest that our identified cell survival/growth-inhibiting
miRNA are downregulated during tumorigenesis, leading to
elevated expression of their survival/growth-inducing target
genes, and thereby, increasing cancer cell survival and/or growth
(Fig. 1e).
Combining the results from both screens, we identified 70
miRNA that had significant dysregulation (1.5-fold-change, BH
adjusted P < 0.05) in ≥5 TCGA cancer types. As our results
suggest overexpression of these miRNA may induce cell death or
inhibit cell growth, we focused on the most relevant miRNA by
determining which had consistent downregulation across
cancers (Fig. 1f). We identified 46 miRNA downregulated at
least twice as frequently as they were upregulated, suggesting
their downregulation may be selected for in the cancer cells. The
same five miRNA (miR-28, miR-30a, miR-139, miR-143, miR-
145) in the RNAi and CRISPR screening data showed both
strands were downregulated across cancer types, indicating their
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downregulation may have allowed for the survival/growth of the
cells that originated from these cancer tissues (Fig. 1g,
Supplementary Tables 3 and 4). The data showed one strand
of miR-30a and miR-145 only had <1.5-fold higher cell survival/
growth association compared with the other strand, suggesting
both strands may function together. Our data also suggest both
strands of miR-30a and miR-145 potentially co-modulate
survival/growth of a higher proportion of cancer cell lines
compared with the other three miRNA 5p/3p pairs.
We determined from the RNAi screening data that 45–61% of
the cell lines were negatively impacted by either the 5p or 3p
strand of miR-30a or miR-145 (Fig. 1g). For the CRISPR
screening data, the range was 70–91% (Fig. 1g). These cell lines
correspond to eight cancer types (BLCA, BRCA, ESCA, LIHC,
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LUAD, LUSC, STAD, UCEC) in TCGA in which miR-30a and/or
miR-145 strands were downregulated (Fig. 1g and Supplementary
Tables 3 and 4). Of the cell lines whose survival/growth were
potentially modulated by miR-30a or miR-145, we investigated
which lines showed association from both strands. We deter-
mined the 5p and 3p strands of miR-30a coordinately associated
with the survival/growth of 65% and 69% of the cell lines in the
RNAi and CRISPR screening data, respectively, that correspond
to 4 cancer types (ESCA, LUAD, LUSC, STAD) (Fig. 1h, i). For
miR-145, both strands coordinately associated with the survival/
growth of 63% and 77% of the cell lines in the RNAi and CRISPR
screening data, respectively, that correspond to 6 cancer types
(BLCA, BRCA, ESCA, LUAD, LUSC, STAD) (Fig. 1h, i).
Combining the results from both screens, we determined that
both strands of miR-30a and miR-145 may coordinately regulate
the survival/growth of 79% and 63% of the cell lines, respectively.
Collectively, we identified a set of miRNA whose both 5p and 3p
strands are associated with cancer cell survival/growth, and the
associations are reproducible in two different platforms. Speci-
fically, this analysis revealed that downregulation of miR-30a and
miR-145 5p/3p pairs may be necessary for pan-cancer cell
survival and/or growth.
miRNA 5p/3p pairs recurrently alter pathways across cancers.
Given the lack of understanding of whether and the extent to
which both strands of individual miRNA can cooperate to reg-
ulate specific cellular pathways that contribute to biological
phenotypic changes in cancer cells, we developed a computational
framework to identify pathways that were significantly impacted
due to miRNA 5p/3p concordant dysregulation. We identified
pan-cancer dysregulation of 26 miRNA 5p/3p pairs that were
significantly dysregulated in ≥5 cancer types compared to cor-
responding normal samples (Supplementary Table 5). Ten had a
trend of global downregulation and the remaining had global
upregulation (Fig. 2a). This analysis revealed there are specific
miRNA 5p/3p pairs that are coordinately up- or downregulated
across different malignancies, suggesting their combined func-
tions may be critical and thus, selected for during tumorigenesis.
We performed pathway enrichment analysis on potential
targets of the above pan-cancer dysregulated miRNA by
determining which have altered expression in cancer compared
with the corresponding normal samples and an inverse expression
association with the potential regulating miRNA (Fig. 2b). We
hypothesize this strategy may capture miRNA-mediated systems-
level biological changes selected for during tumorigenesis. Genes
potentially regulated by the 5p or 3p strand or both in a specific
cancer type were used to determine in which pathways in the
Kyoto Encyclopedia of Genes and Genome (KEGG)29 database
they were significantly (BH adjusted hypergeometric test P < 0.05)
enriched. For 14 different cancers, we identified 178 KEGG
pathways (5p/3p pair–pathway–cancer combinations= 1252) that
were altered in one or more cancer types potentially due to
dysregulation of at least one 5p/3p pair (Fig. 2b). We scored
individual 5p/3p–pathway pairs to statistically determine the
pathways that were coordinately regulated by both strands with
high confidence (Methods; Fig. 2c, d).
We determined the proportion of the target genes in each
pathway that were potentially co-targeted by both 5p and 3p
strands of the specific miRNA. From the pool of pathways that
were coordinately regulated by individual 5p/3p pairs, the
observed distributions prominently clustered the miRNA into
three groups. Four miRNA 5p/3p pairs, including miR-145, co-
target a low proportion (<11%; average fraction of predicted co-
targets present in the specific miRNA-regulated pathway pool) of
their target genes (Fig. 2e, extremely left-skewed density curves),
indicating they preferentially target different genes in the same
pathway. Three miRNA 5p/3p pairs, including miR-17, co-target
a high proportion (54–59%) of their target genes (Fig. 2e,
extremely right-skewed density curves), even though they do not
have identical seed sequences. The remaining 14 miRNA 5p/3p
pairs, including miR-30a, co-target 19–43% of the genes in the
same pathways (Fig. 2e). Therefore, 5p and 3p strands of the
identified miRNA can co-target the same genes or different genes
in the same pathways, and are less likely to compete with each
other compared to miRNA in the same family that have identical
seed sequences.
We investigated the pathways that had recurrent up- or
downregulation potentially due to down- or upregulation of the
specific 5p/3p pairs, respectively. Among the 498 high-confidence
5p/3p–pathway pairs (5p/3p pair–pathway–cancer combinations=
761; Supplementary Table 6), we identified 20 that recurrently
appeared in at least 50% of the cancer types where corresponding
regulating 5p/3p pairs had concordant dysregulation (Fig. 2f, g
and Supplementary Table 6). The top five recurrently associated
5p/3p–pathway pairs were comprised of two upregulated miRNA
that recurrently downregulated three pathways (miR-17-5p/
3p–Proteoglycans in cancer, miR-17-5p/3p–Rap1 signaling, and
miR-93-5p/3p–Vascular smooth muscle contraction) and two
downregulated 5p/3p pairs (miR-30a-5p/3p and miR-145-5p/3p)
that recurrently upregulated cell cycle pathway genes in at least 2/
3rd of the cancer types in which the 5p/3p pairs were dysregulated
(Fig. 2g).
It was previously reported that the miR-17-5p/3p pair
cooperatively regulates TIMP3, a member of the proteoglycans
Fig. 1 Associations between miRNA 5p/3p concordant expression changes and cancer cell viability/growth. a Density plots showing distribution of 5p/
3p expression correlations (green) compared to the background miRNA pairs (red). P-values determined by two-tailed Wilcoxon rank-sum test. b Number
of TCGA normal (N) and tumor (T) samples by cancer type used for analysis. c Scatterplot with regression line, Spearman correlation test score (ρ) and P-
value (two-tailed) indicates degree of global concordance observed in expression fold-changes of 5p/3p pairs across 14 cancer types compared with the
corresponding normal samples. Each dot represents fold-change of one 5p/3p pair in one cancer type. Significant differential expressions of both, one, and
no strands denoted by orange, blue, and gray dots, respectively. d Integrative approach to predict whether individual miRNA target set is enriched with cell
survival/growth-associated genes. e Density plots showing distribution of survival/growth-associated miRNA and gene expression changes in the tumor
tissues compared with the respective normal tissues. Schematic diagram indicates potential association between miRNA downregulation and induced cell
survival/growth. f Pan-cancer (≥5 cancer types) dysregulated miRNA (n= 70) were plotted. Blue and red dots indicate a trend of consistent down and
upregulation, respectively, across the cancer types. Gray dots indicate random up- or downregulation. The proportion of down- or upregulations was
indicated on the x- and y-axis, respectively. Size of individual dots correlates with number of miRNA. g List of miRNA (blue and orange circles) that were
predicted to be associated with cancer cell viability/growth from RNAi or CRISPR screening data. y-axis indicates percentage of the cell lines with which
these miRNA had association. Orange dots represent the 5p and 3p strands of a miRNA that both modulate cancer cell survival/growth. h Empirical
cumulative distribution of cell lines (y-axis) whose survival/growth might be coordinately regulated by the indicated miRNA 5p/3p pairs, as determined by
the GSEA with 10% FDR (x-axis). i Distribution of cancer cells of indicated cancer type whose survival/growth may be regulated by both miR-30a-5p and
3p (left) or both miR-145-5p and 3p (right) as determined from RNAi (top) and CRISPR (bottom) screening data. Dots represent cancer cell lines.
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in cancer pathway. miR-17-5p/3p-mediated suppression of
TIMP3 may contribute to prostate cancer progression, invasion,
and metastasis19,30,31. We determined that elevated levels of the
miR-17-5p/3p pair recurrently suppressed the reported target
gene and pathway across multiple cancers (Supplementary Fig. 4
and Supplementary Table 5). Our results indicate the miR-17-5p/
3p pair may coordinately induce pan-cancer cell migration and
metastasis by suppressing the proteoglycans pathway. For miR-
93, both strands were reported elevated in invasive pituitary
adenoma compared with pituitary adenoma tissue, indicating
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NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-14713-2 ARTICLE
NATURE COMMUNICATIONS |          (2020) 11:968 | https://doi.org/10.1038/s41467-020-14713-2 | www.nature.com/naturecommunications 5
both strands may be dysregulated concordantly in tumorigen-
esis32. For miR-145 and miR-30a 5p/3p pairs, analysis of RNAi
and CRISPR screening data and miRNA-pathway interactions
data across multiple cancer types showed they may regulate the
survival/growth of numerous cancer cell lines by concordantly
modulating the expression of cell cycle pathway genes.
Elevated miR-145 or 30a strands suppress cell cycle pathways.
To further analyze whether our predicted miRNA-mediated
pathway regulations captured the contribution of both 5p and 3p
strands of individual miRNA, we evaluated the two top predicted
miRNA-pathway associations (miR-145-cell cycle and miR-30a-
cell cycle). With the analysis of microarray expression profiles
(GSE48414)33 from the Gene Expression Omnibus database34, we
determined significant downregulation of both miR-145-5p (3.12-
fold-change; P= 2.52 × 10−16; t-test) and miR-145-3p (4.20-fold-
change; P= 2.64 × 10−21; t-test) in the lung adenocarcinoma
patient cohort compared to normal lung tissue (Fig. 3a). Fur-
thermore, analyzing another independent data set (GSE107008),
we determined transcriptome-wide mRNA expression changes
induced by overexpression of either the miR-145-5p or 3p strand
in LUAD and ESCA cancer cell lines. Using GSEA with the gene
sets available in the KEGG or Reactome35 databases, we deter-
mined that overexpression of miR-145-5p or miR-145-3p resulted
in suppression of pathways involved in cell cycle progression
(Fig. 3b). Cell cycle, DNA replication, and mitotic cell cycle were
among the top ten downregulated pathways that significantly
decreased (FDR= 0) with increased expression of miR-145-5p or
miR-145-3p in both LUAD and ESCA cancer cell lines.
From the independent microarray expression profiles, we also
determined significant downregulation of both miR-30a-5p (4.23-
fold-change; P= 1.0 × 10−19; t-test) and miR-30a-3p (5.97-fold-
change; P= 7.08 × 10−25; t-test) in lung adenocarcinoma patient
samples compared to normal lung tissue (Fig. 3c)33. Furthermore,
using quantitative reverse transcription PCR (qRT-PCR) we
confirmed significant downregulation of both miR-30a-5p (P=
1.98 × 10−6; t-test) and miR-30a-3p (P= 2.60 × 10−8, t-test) in
our own lung adenocarcinoma patient cohort compared to
normal lung tissue (Fig. 3d). Similarly, we determined levels of
miR-30a-5p and miR-30a-3p were significantly (P < 6.63 × 10−4,
t-test) reduced across a panel of lung adenocarcinoma cell lines
compared to a normal bronchial epithelial cell line (Fig. 3e).
To gain insight into regulatory mechanisms of individual
miRNA strands, we performed whole transcriptome RNA-
sequencing expression profiling following transfection of miR-
30a-5p or miR-30a-3p mimics into A549 lung adenocarcinoma
cells and evaluated transcriptome-wide mRNA expression
changes compared to samples with a negative control RNA.
Using GSEA, based on KEGG and Reactome databases, we
determined several cell cycle-linked pathways, including cell
cycle, mitotic cell cycle, DNA replication, mitotic prometaphase,
and mitotic M-M/G1 phase were in the top ten pathway list that
were significantly (FDR < 0.05 for KEGG and FDR= 0 for
Reactome) downregulated in both miR-30a-5p and miR-30a-3p
transfected lung adenocarcinoma cells (Fig. 3f).
The cell cycle pathway was predicted to be regulated by miR-
145-5p/3p in 6 different TCGA cancers (BLCA, ESCA, LUAD,
LUSC, STAD, UCEC) and by miR-30a-5p/3p in four cancers
(ESCA, LUAD, LUSC, STAD). We assessed variation of cell cycle
pathway activation levels in individual tumor samples of these
cancer types using single-sample gene set enrichment analysis
(SSGSEA)36. We determined that individual patients with higher
cell cycle activation signals had significantly lower expression of
miR-145-5p, miR-145-3p, miR-30a-5p, and miR-30a-3p com-
pared to patients with a lower cell cycle activation signal of the
above cancer types, except UCEC (Supplementary Fig. 5a, b).
Therefore, using independent lung cancer validation data, we
verified decreased levels of individual strands of both miR-145
and miR-30a in multiple cancers. Furthermore, using perturba-
tion data, we verified that elevated expression of these individual
mature strands results in suppression of cell cycle pathways.
miR-30a strands hinder lung cancer proliferation and move-
ment. As previous reports confirmed increased miR-145-5p and
miR-145-3p expression decreases proliferation and movement
of lung adenocarcinoma37, lung squamous cell carcinoma38,
and bladder cancer39 cell lines, we focused on miR-30a28. Our
RNA-seq data revealed significantly downregulated genes (≥2-
fold-change with BH adjusted P < 0.05) either in miR-30a-5p or
miR-30a-3p transfected lung adenocarcinoma cells compared to
the cells transfected with negative control RNA. These genes were
significantly enriched, as determined by the WebGestalt tool28,
with critical gene ontology biological processes that induce cell
growth and movement (Fig. 4a, Supplementary Table 7). Upre-
gulated genes were enriched with the gene ontology terms that
suppress cell movement (Supplementary Table 8). These results
suggest elevated miR-30a-5p and miR-30a-3p may suppress
LUAD cell proliferation and movement. To evaluate the biolo-
gical effects of miR-30a-5p and 3p on lung cancer cell growth, we
separately overexpressed these miRNA in two lung cancer cell
lines (A549 and H1993) that had reduced endogenous levels of
these miRNA strands (Fig. 3e). Increased levels of either miR-
30a-5p or 3p at two different concentrations resulted in decreased
lung cancer cell growth compared to the control RNA in both
lung cancer lines (Fig. 4b and Supplementary Fig. 6). To test the
biological effects of miR-30a on cell movement, we overexpressed
each strand individually or control RNA and performed transwell
migration assays. As previously reported, miR-30a-5p inhibited
cell migration in A549 cells40. Overexpression of miR-30a-3p also
inhibited cell migration, but to a greater extent than miR-30a-5p,
indicating both strands independently control cell movement
(Fig. 4c). These data further demonstrate that both strands of
miR-30a contribute to cancer cell proliferation and migration.
Both miR-145 and 30a 5p/3p pairs cooperate in lung cancer.
Since pathways can be modulated by changes in gene expression
due to genetic alterations (e.g., copy number) or epigenetic mod-
ification (e.g., methylation), we investigated whether miR-30a and
miR-145-mediated cell cycle pathway modulation in 14 TCGA
cancer types were influenced by such modifications. We conducted
a multivariate regression analysis to determine miRNA-mediated
mRNA expression changes accounting for the noise from copy
number changes and DNA methylation (Fig. 5a). For LUAD, we
identified predicted target mRNA that had significant negative
associations (BH adjusted regression P < 0.05) with miR-30a-5p,
30a-3p, 145-5p, and 145-3p. We determined that each miRNA
strand significantly suppressed a subset of the previously reported
gold-standard common essential genes41. These predicted target
essential genes were significantly more depleted in cells with ele-
vated regulating miRNA compared with the remaining genes (P <
3.3 × 10−9; two-tailed Kolmogorov–Smironov test; Fig. 5b and
Supplementary Fig. 7). Using the Rank product statistic, we iden-
tified miRNA-target association recurrence across the 14 cancer
types with statistical significance (BH adjusted Rank product P <
0.05; Fig. 5a)42,43. These recurrently and inversely associated genes
were significantly enriched with cell cycle pathways for both miR-
30a and miR-145 (Fig. 5c). The results suggest pan-cancer sup-
pression of cell cycle pathway genes by miR-145 and miR-30a 5p/
3p pairs are independent from DNA copy number and methyla-
tion changes.
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To estimate the impact of 5p/3p combined-mediated regula-
tion of gene expression, we stratified patient samples from
individual cancer types into lower and higher groups based on
median expression of miR-30a-5p and miR-30a-3p. If both
strands had either lower expression or higher expression in a set
of samples, we denoted those samples as low or high, respectively.
The remaining samples were denoted as mixed type. Notably, we
observed cell cycle regulating genes recurrently associated with
both miR-30a-5p and 3p had higher expression in the low-sample
group and lower expression in the high sample group across
cancer types (Fig. 5d, e). There was intermediate expression in the
mixed group (Fig. 5e). Therefore, alteration of both strands of
miR-30a may have a greater impact on cell cycle pathway genes
than a single strand.
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To evaluate the biological consequences when both strands of
miR-30a are dysregulated, we simultaneously overexpressed miR-
30a-5p and miR-30a-3p in A549 and H1993 lung cancer cell lines.
There was a further decrease in cell growth when both 5p and 3p
were increased together compared to when each was overexpressed
alone, indicating a cooperative effect (Fig. 6a and Supplementary
Fig. 8a). Moreover, the combination of both miR-30a-5p and miR-
30a-3p at a lower concentration resulted in either a similar
effect (H1993 cells) or a greater negative effect (A549 cells) on cell
growth compared to when either miR-30a-5p or miR-30a-3p were
overexpressed individually at twice the concentration (Fig. 6b). To
test the effects on cell migration, A549 cells were transfected with
one or both strands of miR-30a. Transwell migration assays showed
that both miR-30a-5p and miR-30a-3p together had a cooperative
negative effect on lung cancer cell migration (Fig. 6c). These data
show that concordant downregulation of both miR-30a strands
work together to increase cancer cell growth and migration, which
would be predicted to negatively impact patients.
To investigate potential cooperativity between 5p and 3p
strands of both miR-30a and miR-145, we simultaneously
Fig. 3 Individual strands of miR-145 and miR-30a independently modulate cell cycle-associated pathways. a, c Microarray to measure expression
differences of miR-145-5p (*P= 2.52 × 10−16; a top), miR-145-3p (**P= 2.64 × 10−21; a bottom), miR-30a-5p (*P= 1.0 × 10−19; c top), and miR-30a-3p
(**P= 7.08 × 10−25; c bottom) in an independent cohort of lung adenocarcinoma patient samples (n= 154) compared to normal (n= 20) lung tissue; two-
tailed t-tests. b, f GSEA demonstrated downregulated pathways in miR-145-5p or miR-145-3p transfected A549 cells (b top) or TE8 cells (b bottom), and
miR-30a-5p or miR-30a-3p transfected A549 cells (f), compared to the control cell line. Pathways were ranked (x-axis) on the basis of negative normalized
enrichment scores (y-axis). Cell cycle-associated pathways that are within the top ten pathway list, are indicated and were significantly enriched (FDR <
0.05). d qRT-PCR (in triplicate) for miR-30a-5p (top) and miR-30a-3p (bottom) expression in patient samples of lung adenocarcinoma and normal lung
tissue. Individual samples (left) and mean expression (right) shown; *P= 1.98 × 10−6, **P= 2.60 × 10−8, two-tailed t-tests. e qRT-PCR (in triplicate) for
miR-30a-5p (top) and miR-30a-3p (bottom) levels in lung adenocarcinoma lines and a normal bronchial epithelial line; #P= 6.62 × 10−4, *P < 6.05 × 10−6,
two-tailed t-tests. For qRT-PCR (d and e), miRNA expression was normalized to endogenous small RNA RNU6B and presented as 2−ΔCt. Data are
presented as mean values ± SEM in a and c–e. Source data are provided as a Source Data file.
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overexpressed all four strands in A549 and H1993 lung cancer
cell lines. Using two different concentrations, we observed that
cell growth was significantly reduced in both cell lines when all
four miRNA strands were overexpressed compared to over-
expression of both the 5p and 3p strands of miR-30a or both the
5p and 3p strands of miR-145 (Fig. 6d and Supplementary Fig. 8b,
c). Notably, combining all four strands at a lower concentration
(25 nM each) had a greater negative impact on cell growth than
both strands of either miRNA combined at a higher concentra-
tion (50 nM each) (Fig. 6d). Similarly, in colony formation assays,
there were fewer colonies of A549 lung cancer cells over-
expressing all four miRNA strands compared to A549 cells
overexpressing both 5p and 3p strands of either miR-30a or miR-
145 (Fig. 6e). Cooperativity was also observed among all four
miRNA strands in migration assays, as migration of A549 cells
was further reduced when both 5p and 3p strands of both miRNA
were overexpressed compared to overexpression of the 5p and 3p
strands of miR-30a or miR-145 (Fig. 6f). Collectively, these data
show cooperation between both strands of miR-30a and miR-145
impact tumor cell proliferation and migration.
Novel miRNA signature links to pan-cancer patient survival.
Given that miR-145 and miR-30a 5p/3p pairs had pan-cancer
downregulation in association with overlapping oncogenic bio-
logical processes, they may constitute an oncogenic miRNA
signature44,45. To evaluate whether expression of these miRNA
correlate with patient overall survival, we averaged the expression
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Fig. 6 Cooperation of all four strands of miR-30a and miR-145 in cancer cell growth and movement. Lung adenocarcinoma lines transfected with miR-
30a-5p, miR-30a-3p, miR-145-5p, and/or miR-145-3p miRNA mimic, or control RNA at the indicated concentrations. Control RNA was also added to
equalize the total amount of RNA transfected. a, b, d MTT assays performed at intervals, in quadruplicate. Each assay was performed 2–4 independent
times for both cell lines and one representative experiment is shown. For a, A549 *P < 6.18 × 10−5, H1993 *P < 2.36 × 10−2 (comparing 5p+ 3p to 5p or 3p
alone); for b, A549 *P < 9.21 × 10−6, H1993 *P < 1.91 × 10−2 (comparing 5p+ 3p to 5p or 3p alone at both concentrations); for d, A549 *P < 1.69 × 10−4 and
**P < 7.02 × 10−5, H1993 *P < 4.27 × 10−4 and **P < 2.82 × 10−3 (*, comparing 30a-5p/3p+145-5p/3p to 30a-5p/3p or 145-5p/3p at both concentrations
and **, comparing 25 nM 30a-5p/3p+145-5p/3p to 50 nM 30a-5p/3p or 145-5p/3p); two-tailed t-tests. c, f Transwell migration assays were performed 2
(c) or 4 (f) independent times and results from one representative experiment are shown for each. For c, *P= 2.3 × 10−3 and **P= 2.0 × 10−4; for f,
P-values indicated; two-tailed t-tests. Representative images shown in f (x10 magnification; scale bars, 200 μm). e Colony formation assays were
performed two independent times, in triplicate, and a representative experiment and images (no magnification) are shown. P-values indicated; two-tailed t-
tests. Data are presented as mean values ± SEM; error bars are within the symbols in a, b, and d. Source data are provided as a Source Data file.
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of miR-145-5p, miR-145-3p, miR-30a-5p, and miR-30a-3p for
each TCGA patient. For a specific cancer type, we ranked the
patients according to the average miRNA expression and divided
them into four equal quartiles. Univariate survival analysis
showed that patients with low signature miRNA expression
(lowest quartile group) had significantly reduced overall survival
compared with patients that had high signature miRNA expres-
sion (highest quartile group) for five cancer types: KIRC (P=
6.37 × 10−4; log-rank test, hazard ratio [HR]= 0.27), CHOL (P=
7.59 × 10−3, HR= 0.09), LUSC (P= 5.09 × 10−3, HR= 0.45),
LUAD (P= 0.01, HR= 0.48), and BRCA (P= 0.06, HR= 0.51)
(Fig. 7 and Table 1). FDR adjusted survival P-values shown in
Fig. 7. For LUAD and LUSC, two aggressive cancer types, the
median survival decreased by 51.5 months (54.1 vs. 105.6) and
20.9 months (55.2 vs. 76.1), respectively, when the miRNA levels
were low. We conducted the same analysis considering the
expression of a single strand or both strands of miR-145 or miR-
30a. We observed a significantly (P= 2.51 × 10−3; Wilcoxon
rank-sum test) stronger association between reduced overall
survival and downregulation of all four mature strands together
compared with the association observed between poor overall
survival and downregulation of a single strand or both strands of
miR-145 or miR-30a (Supplementary Table 9). Subsequent
multivariate cox regression analysis considering miRNA signature
expression, patient age, tumor grade, and tumor stage informa-
tion (if available) determined the expression of these miRNA
independently correlated with poor overall survival with statis-
tical significance (P < 0.05, Wald test; HR < 0.56; Table 1). Eva-
luation of the other miRNA we identified, which cooperatively
regulate the same critical oncogenic pathways (Supplementary
Table 6), showed that none had an equivalent or superior survival
association as that of the miR-145/30a 5p/3p combination, indi-
cating this miRNA signature is unique. These results indicate the
expression of the four strands of miR-145 and miR-30a constitute
a signature that is a predictive indicator of overall survival in
patients across diverse cancer types. Altogether, the data reveal
that miR-145-5p, miR-145-3p, miR-30a-5p, and miR-30a-3p are
coordinately downregulated by multiple cancers due to their
regulation of core processes that inhibit tumorigenesis and tumor
progression that significantly contribute to patient survival.
Discussion
Despite miRNA sequencing data showing miRNA biogenesis
produces significant quantities of mature miRNA from both the
5p and 3p strands from miRNA duplexes4,5, very little is known
about their combined functions and regulatory mechanisms in
cancer and other diseases. Here, we identified 26 miRNA 5p/3p
pairs that had concordant dysregulation across multiple cancer
types, indicating they may be selected for during tumorigenesis.
We have carried out a comprehensive, rigorous analysis of human
transcriptomic, genomic, epigenetic, and gene perturbation data
across 14 TCGA cancer types to gain insight into the roles of
these miRNA 5p/3p pairs in cancer. We established links between
frequently dysregulated miRNA 5p/3p pairs and tumorigenesis in
two different ways, adding significant power to our analysis.
Firstly, we exploited cell viability/growth screens that established
essential gene signatures, and linked those genes with potentially
regulating miRNA by developing a novel computational frame-
work. Utilizing RNAi and CRISPR, two independent screening
platforms, we determined reproducible associations between
miRNA 5p/3p dysregulation and modulation of cancer cell via-
bility/growth across cancers. Secondly, we conducted a rigorous
data analysis that incorporated pathway information in the dys-
regulated miRNA and mRNA networks across cancer types to
determine specific miRNA 5p/3p pairs that may coordinately
regulate the same pathways that contribute to tumorigenesis. We
derived previously unidentified, high-confidence miRNA 5p/3p-
mediated pathway regulations in 14 cancer types and made them
publicly available, allowing for further exploration of the candi-
date miRNA 5p/3p–pathway interactions in TCGA data. We also
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Fig. 7 A four-miRNA expression signature correlates with patient overall survival across diverse cancer types. Kaplan–Meier plots of overall survival
according to a survival predictor based on the average expression of miR-145-5p, miR-145-3p, miR-30a-5p, and miR-30a-3p. For each cancer type, patient
samples were ranked according to the average expression of the four miRNA and divided into four quartiles. Lowest (blue lines) and highest (orange lines)
quartile groups were used for Kaplan–Meier survival analyses; statistical significance was measured using log-rank test. False-discovery rate (FDR) values
were determined.
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identified recurrent cancer-associated miRNA 5p/3p–pathway
relationships. Determining recurrence of miRNA-pathway asso-
ciations across cancer types itself is a powerful approach because
it detects results that are reproducible in different cancers. The
reproducible results that we observed in both analyses most likely
indicate true biological events and minimize false-positives46–48.
Taken together, these two massive-scale data analyses allowed us
to pinpoint miRNA 5p/3p pairs whose dysregulation may con-
sequently drive pathway/systems-level changes to favor cancer
cells for survival, growth, and progression, referred to as phe-
notypic plasticity in cancer49.
In both the analyses evaluating miRNA 5p/3p cooperativity,
miR-145 and miR-30a appeared in the top prediction results.
Their expression showed a negative impact on the viability/
growth of diverse cancer cell lines and they independently ele-
vated cell cycle regulating pathway genes in 2/3rd of the cancer
types in which they were downregulated. We determined that
these miRNA-pathway gene associations were independent from
the impact of DNA copy number and methylation changes and
are consistent across the 14 cancer types using a robust rank
product statistic42,43. With high statistical power and follow-up
experiments in every step of the analysis, there is high confidence
in our results.
Analysis of 531 heterogeneous normal tissues from 14 TCGA
cancer types revealed that individual strands of miR-145 and
miR-30a had 23-fold higher expression than the threshold to
detect high-confidence miRNA4,50. In fact, miR-145-5p, miR-
30a-5p, and miR-30a-3p are among the top 30 miRNA that
constitute, on average, 90% of all miRNA expression across the
normal tissues in TCGA21. Our study examined whether indivi-
dual strands of high-confidence miR-145 and miR-30a can
independently suppress the genes in crucial tumorigenic pro-
cesses. From the miRNA perturbation profiles in LUAD (miR-
145 and miR-30a) and ESCA cell lines (miR-145), we determined
that elevated expression of both 5p and 3p strands independently
suppressed an enriched number of cell cycle-associated pathway
genes. We observed consistent downregulation of miR-145 5p/3p
pairs in TCGA, as well as in an independent LUAD patient
cohort34. Previously, it was reported that decreased levels of miR-
145-5p and miR-145-3p increase proliferation and movement of
LUAD37, LUSC38, and BLCA39 cells. In support of this, we
showed that forced expression of both strands of miR-145
decreased lung adenocarcinoma cell growth and migration.
Expression and functions of miR-30a 5p/3p pairs were unknown,
but our data showed reduced levels in a panel of LUAD cell lines
and in our own lung cancer patient samples. We also determined
miR-30a-5p and 3p forced expression consequently reduced lung
cancer cell proliferation and movement. Collectively, our data
show that both strands of a miRNA can be abundantly expressed
across tissue types, and they are capable of modulating tumori-
genic processes independently and cooperatively.
Our comprehensive data analysis highlights that miRNA 5p/3p
pairs, which do not have identical mRNA-targeting seed
sequences, coordinately regulate the same pathways by targeting
different genes in the pathway or the same genes at different sites.
We determined from a pool of miR-145-5p/3p–pathway asso-
ciations that only ∼10% of the pathway genes were potentially
co-regulated by both strands. It was slightly higher (28%) for
miR-30a. Therefore, simultaneous downregulation of these
miRNA might impact a larger spectrum of genes in specific
biological processes compared to the single strand alone. These
results also highlight a potential caveat of retroviral or transgene
miRNA overexpression data, as both strands will be over-
expressed, but typically only levels and targets of one strand are
evaluated. Our data confirmed cooperative effects in the mod-
ulation of lung cancer cell growth and movement when both
strands of miR-30a and miR-145 were perturbed simultaneously.
Our results also expose cooperativity between all four strands of
miR-30a and miR-145, since the four strands together had a
larger impact on tumor cell proliferation and movement than
both strands of either miR-30a or miR-145 alone. Furthermore,
coordinated downregulation of miR-145 and miR-30a 5p/3p pairs
Table 1 Analysis of 10-year overall survival in patients of diverse TCGA cancer types.
Cancer type Variables Univariate Multivariate
HRa 95% CIb P-valuec HR 95% CI P-valued
KIRC Age 1.1 0.54–2.25 0.80
Tumor gradee 4.17 1.45–11.96 3.89E-03 2.35 0.80–6.92 0.12
Tumor stagef 10.19 3.90–26.63 4.61E-09 8.38 3.16–22.22 1.93E-05
miRNA expressiong 0.27 0.12–0.60 6.37E-04 0.29 0.12–0.66 3.35E-03
LUSC Age 0.74 0.42–1.30 0.30
Tumor stage 1.56 0.82–2.97 0.17
miRNA expression 0.45 0.26–0.80 5.09E-03
CHOL Age 2.24 0.54–9.35 0.26
Tumor grade 0.99 0.21–4.65 0.99
Tumor stage 2.27 0.61–8.52 0.2
miRNA expression 0.09 0.01–0.79 7.59E-03
LUAD Age 0.98 0.56–1.69 0.93
Tumor grade
Tumor stage 3.02 1.71–5.32 5.95E-05 2.74 1.55–4.87 5.56E-04
miRNA expression 0.48 0.27–0.86 0.01 0.55 0.31–0.97 0.04
BRCA Age 1.93 0.94–3.95 0.07
Tumor stage 4.04 1.99–8.19 2.77E-05
miRNA expression 0.51 0.25–1.06 0.06
aHR hazard ratio.
bCI confidence interval.
cLog-rank test P.
dWald test P.
eHistological grade.
fEarly stages (I and II) vs. late stages (III and IV).
gSample-wise average expression of miR-145-5p, miR-145-3p, miR-30a-5p, and miR-30a-3p. Samples were stratified into lowest quartile and highest quartile.
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were an independent prognostic factor, resulting in patients with
worse overall survival in multiple cancer types. Collectively, our
multiple approaches with corresponding verification identified a
new clinically relevant pan-cancer miRNA signature that had
remained unidentified due to a lack of understanding of 5p and
3p strand-mediated cooperativity.
Methods
Analysis of TCGA transcriptomic data. We extracted and processed miRNA-seq
and mRNA-seq expression profiles of 14 TCGA cancer types. For each cancer type,
we selected miRNA or mRNA for the downstream analysis if at least 50% of the
samples had a normalized expression value ≥1. We used normalized expression
profiles, for miRNA-seq-Reads Per Million Mapped Reads and for mRNA-seq-
Reads Per Kilobase Million Mapped Reads, to measure miRNA-miRNA and
miRNA–mRNA expression associations using Spearman’s rank correlation
method. We used raw read counts to measure differential expression of miRNA
and mRNA. We employed the R/Bioconductor package edgeR for differential
expression analysis51. In edgeR, the data were normalized based on negative
binomial distribution. Differential expression of miRNA or mRNA between tumor
and corresponding normal samples was assessed by estimating an exact test P-
value, which is similar to the Fisher’s exact test. The results were further adjusted
using the Benjamini–Hochberg (BH) multiple testing correction method23. The
mRNA were regarded as significantly differentially expressed in cancer compared
with the normal tissue if they had at least 2-fold-change with BH adjusted P < 0.05.
For miRNA, we used a cutoff of 1.5-fold-change with BH adjusted P < 0.05 since
miRNA with 1.5-fold-change are reported to have significant impact on cellular
processes52.
Prediction of cancer-specific dysregulated miRNA–mRNA pairs. We extracted
genome-wide predicted targets of miRNA from TargetScan (version 7.1)53 and our
previously developed miRNA-target prediction tool TargetMiner54. Additionally,
we extracted high-confidence miRNA-targets from miRTarBase database that
curated experimentally verified miRNA-gene interactions55. We took the union set
of these three. For each cancer type, we predicted miRNA-mediated suppression of
potential target genes by employing the following strategy: if the miRNA were
significantly downregulated (at least 1.5-fold-change with BH adjusted P < 0.05),
the predicted target genes should be significantly upregulated (at least 2-fold-
change with BH adjusted P < 0.05) or vice-versa. Furthermore, the miRNA-gene
pairs were required to be inversely correlated. This strategy identified cancer-
specific miRNA-mediated potential supppression of the critical genes, which likely
minimizes false-positives and captures the most important regulations in the
context of cancer.
Identification of cell survival/growth modulating miRNA. We extracted
genome-scale RNAi screening data on 712 cancer cell lines (Release- DEMETER2
Data v5) from Depmap database. From this database we also extracted genome-
scale CRISPR screening data on 563 cancer cell lines (Release- Depmap Public
19Q2). Dependency scores for ~17,000 genes in a given cell line were determined
by the algorithm DEMETER225 for RNAi and the algorithm CERES26 for CRISPR.
For the screening data, a lower score or rank means a given cell line is more likely
to be dependent on that gene for its growth/survival. For individual cell lines, we
ranked the ~17,000 genes based on their viability/growth scores determined from
RNAi or CRISPR-mediated knockdown screens24–26. Cell lines in the RNAi or
CRISPR screening data that originated from one of the 14 TCGA primary tumor
sites we studied here were initially selected for this analysis. However, among the
14 cancer types, 5 were excluded from the analysis due to an insufficient number of
cell lines (range 0–4). Finally, we evaluated 251 RNAi and 177 CRISPR screened
cell lines, respectively (290 unique cell lines) that originated from 9 primary tumor
sites. Our approach integrated (a) RNAi or CRISPR screening data of cell lines
originating from a primary tumor site i, (b) predicted miRNA-target networks that
were dysregulated and had significant (BH adjusted P < 0.05) inverse Spearman’s
rank correlations in i, and (c) gene set enrichment analysis (GSEA)27 method,
embedded into R package WebGestaltR28 (Fig. 1d). Unlike traditional GSEA that
uses curated pathways as gene sets, here we used targets of individual mature
miRNA as the gene set. For a given miRNA and cell line pair, we implemented the
GSEA approach on the ranked gene list and the miRNA-target gene set. The gene
sets with significantly (FDR < 0.1) negative NES indicate they were overrepresented
at the bottom of the ranked gene list.
miRNA 5p/3p−pathway associations. Differentially expressed genes that were
potentially regulated by either 5p or 3p or both strands of a precursor miRNA in a
specific cancer type were selected to conduct pathway enrichment analysis using
the canonical KEGG pathway database29, which is embedded into WebGestaltR, an
R package of the web-server WebGestalt28. The pathways significantly enriched
(BH adjusted hypergeometric test P < 0.05) with the predicted target genes were
filtered as follows to obtain the high-confidence 5p/3p–pathway combinations.
First, we examined whether the predicted miRNA-target genes had significantly
stronger (BH adjusted P < 10−3; Wilcoxon rank-sum test) inverse associations,
measured by the Spearman’s rank correlations, compared to the 10,000 randomly
selected miRNA-gene pairs. The genes in the randomly generated data set may or
may not have predicted miRNA-binding sites of the corresponding miRNA. Sec-
ond, we determined what proportion of the genes in a pathway were predicted to
be targeted by the 5p or the 3p strand. Absolute difference between these two
proportion values were taken where the lower the score indicates the greater the
5p/3p pair mediated coordinated regulation of the pathway. We selected those 5p/
3p pair−pathway combinations that had the score <0.5. Third, we examined fre-
quency of the 5p/3p pair−pathway association across the cancer types in which the
miRNA 5p/3p pair was concordantly dysregulated. The higher the scores indicate
the pathways are more recurrently dysregulated potentially due to concordant
dysregulation of the regulating 5p/3p pairs.
Multivariate regression analysis. We collected processed DNA methylation and
copy number profiles of 14 TCGA cancer types from the UCSC Xena database. To
determine whether mRNA (Y) and its predicted regulating miRNA ðxmiRm Þ
expression association in the n tumor samples of a given cancer type was inde-
pendent of DNA methylation (xDM) and copy number (xCNV) change events, we
performed the following multivariate regression analysis:
Ys ¼ β0 þ βDMxDM;s þ βCNVxCNV;s þ βmiRm xmiRm ;s ; s ¼ 1; ¼ ; n
here β0 is the intercept. βDM; βCNV; and βmiRm are the regression coefficients that
indicate the association strength between RNA level expression change of the given
gene with DNA methylation, copy number, and miRNA expression changes,
respectively. For a specific cancer type, we used BH adjusted regression P < 0.05 as
the cutoff to select significantly associated miRNA–mRNA pairs.
Predicting recurrent miRNA–mRNA associations across cancers. The
miRNA–mRNA regression coefficients obtained from 14 cancer types were collated
into a matrix format and input into the RankProducts function in the R package
RankProd42. The coefficient values were ranked from most negative to most
positive, and most positive to most negative. The rank product statistic, described
by Breitling et al.43, was then used to identify recurrence of miRNA–mRNA
associations with statistical significance across the cancer types. The nominal P-
values obtained from this analysis were further corrected using BH multiple test
correction method. Consistent inverse associations across the 14 cancer types with
BH adjusted P < 0.05 were selected as miRNA–mRNA association recurrence.
Cell culture and transfections. Lung cell lines were cultured in RPMI-1640 media
supplemented with 10% FBS and penicillin/streptomycin (H460, H2087, H2110,
H441, PC9, and H1299) and with additional L-glutamine (Beas2B, A549, H1993,
and H1435). All cell lines were verified to be mycoplasma negative. Lipofectamine
2000 (Invitrogen) was used to transfect A549 and H1993 lung cancer cell lines with
either 25, 50, or 100 nM miR-30a-5p, miR-30a-3p, miR-145-5p, or miR-145-3p
miRNA mimic, negative control RNA mimic, or a combination (Dharmacon),
according to the manufacturer’s protocol using the 6-well plate format.
RNA isolation and qRT-PCR. RNA was isolated from cells and tissue using TRIzol
(Ambion) according to the manufacturer’s protocol with one modification. To
enrich for miRNA, the isopropanol incubation step was performed overnight at
−20 °C. To measure expression of miR-30a-5p and miR-30a-3p by qRT-PCR,
TaqMan MicroRNA Assays (Applied Biosystems) were performed in triplicate.
miRNA expression was normalized to the small RNA RNU6B as an endogenous
control and is presented as 2−ΔCt.
RNA-sequencing data analysis. Triplicate samples were harvested 72 h after
transfection of miR-30a-5p or miR-30a-3p miRNA mimic or control RNA into
A549 cells. RNA-seq profiles, generated from Illumina Novaseq 6000 system, were
obtained from Novogene (https://en.novogene.com/). Sequence mapping and
quantification were performed using the methods STAR (V2.5)56 and HTSeq
(V0.6.1)57, respectively. For sequence mapping, Human reference genome version
hg19 was used. The read counts were imported into edgeR for differential
expression analysis51. In edgeR, data were normalized based on negative binomial
distribution. Differential expression of genes between miR-30a-5p or miR-30a-3p
mimic and negative control RNA samples was assessed by estimating an exact test
P-value. The results were further adjusted using the BH multiple testing correction
method.
Cell proliferation assay. Lung adenocarcinoma cells (A549 and H1993) were
transfected with individual miRNA mimics (25, 50, or 100 nM), a combination of
miRNA mimics, and/or negative control RNA (equal amounts of RNA were
transfected for each experiment). Cells were trypsinized, and 2500 cells/well were
placed into 96-well plates, in quadruplicate. Once cells attached, the 0 h time was
measured by MTT (Sigma) assay (approximately 24 h after transfection). MTT
assays were performed every 24 h thereafter. Absorbance was measured at 562 nm.
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Colony formation assay. Lung adenocarcinoma cells (A549) were transfected with
individual miRNA mimics (25 nM), a combination of miRNA mimics, and/or
negative control RNA (equal amounts of RNA were transfected for each experi-
ment). Twenty-four hours after transfection, cells were trypsinized, counted, and
seeded at low density (300 cells/well) into 6-well plates, in triplicate. After 12 days
in culture, colonies were stained using crystal violet and were counted (≥50 cells
defined a colony) using an inverted microscope.
Cell migration assay. Lung adenocarcinoma cells (A549) were transfected with
miRNA mimics (25 or 50 nM) separately or in combination and/or negative
control RNA (equal amounts of RNA were transfected for each experiment).
Twenty-four hours later, 4 × 104 cells were resuspended in serum-free RPMI-1640,
placed into migration chambers (8 μm pores, BioCoat Insert), and transwell
migration assays were performed, as we reported previously47,58. Specifically,
inserts were stained 18 h later using Siemens Diff-Quick staining set and protocol
and blinded. Migrated cells per field were counted (at least four independent fields
per sample) using an Olympus CKX53 inverted microscope (10x objective).
Patient sample acquisition. De-identified frozen patient samples of non-small-cell
lung adenocarcinoma (stages 3 and 4) and normal lung were obtained from the
Vanderbilt University Medical Center Lung Biorepository. All patient samples were
from surgical resections and were banked with patient consent. All samples were
evaluated by a board-certified pathologist and were either determined to be >80%
tumor (for tumor samples) or to lack any precancerous lesions (for normal sam-
ples) via H&E-stained sections.
Statistics. Unpaired, two-tailed t-tests were used when comparing two groups and
P-values of <0.05 were considered statistically significant. Differential expression
analysis of miRNA and mRNA between normal and cancer tissues from TCGA and
the differential expression analysis of mRNA between miR-30a-5p and -3p mimics
and negative control RNA in the A549 cell line were performed with edgeR51. Other
statistical tests are indicated explicitly. For the biological assays (MTT, colony,
migration, and qRT-PCR), data are presented as mean values ± SEM.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Data supporting the findings of this study are available within the paper and
its Supplementary Information files. The RNA-sequencing data are available from Gene
Expression Omnibus (GEO) and NCBI Sequence Archive (SRA) databases, GSE142695
and SRP238971. All other publicly available data referenced herein can be retrieved from
GEO (https://www.ncbi.nlm.nih.gov/gds/), TCGA (https://portal.gdc.cancer.gov/), and
the following websites- Depmap (https://depmap.org/portal), Xena (https://xena.ucsc.
edu/), WebGestalt (http://www.webgestalt.org/). The Source Data for Figs. 3a, c–e, 4b, c,
5e, and 6a–f, and Supplementary Figs. 5a, b, 6 and 8a–c are provided as a Source
Data file.
Code availability
We make extensive use of previously published algorithms as described in the Methods
and Results section. Additional code used in this study is available upon request.
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